Fonseca de Jesus VH, et al. - Researchers assessed the outcomes of 42 adult patients with metastatic pancreatic adenocarcinoma (MPA) who were treated with FOLFIRINOX in the first-line setting but experienced disease progression, with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0–2, and were treated with ≥ 1 cycle of gemcitabine-based chemotherapy in second or further lines of treatment thereafter. Findings demonstrated the benefits of gemcitabine-based regimens following FOLFIRINOX in a subgroup of patients with MPA. Compared with single-agent gemcitabine, the investigators noted superior outcomes with gemcitabine-based combinations, particularly gemcitabine plus nab-paclitaxel. They recommended that treatment in this setting should be offered carefully to patients with an ECOG PS score of 2 owing to shorter survival and increased risk of toxicity.